Exhibit 99.1

Lifeloc Reports Third Quarter 2025 Results

WHEAT RIDGE, Colo., November 12, 2025 -- Lifeloc Technologies, Inc. (OTC: LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, has announced financial results for the quarter ended September 30, 2025.

Third Quarter Financial Highlights

Lifeloc posted quarterly net revenue of $2.257 million in the third quarter of 2025, resulting in a quarterly net loss of $(263) thousand, or $(0.10) per diluted share. These results compare to net revenue of $2.087 million and quarterly net loss of $(158) thousand, or $(0.06) per diluted share in the third quarter of 2024. Revenue for the quarter increased 8% versus the third quarter last year. Nine-month 2025 net revenues of $6.754 million and a net loss of $(950) thousand, or $(0.35) per diluted share, compared to net revenue of $6.628 million and a net loss of $(740) thousand, or $(0.30) per diluted share, for the same nine months of 2024. Total gross margin in the third quarter decreased to 40.2% versus 43.7% for the same quarter last year. For the first nine months of 2025 gross margin was 40.6% versus 41.4% for the same period last year.

The margin decline for 2025 was a result of general cost inflation and tariffs which the company is working to address through pricing. The losses for the quarter and year to date were caused primarily by the high research and development costs with the push to commercialize our SpinDetect™ centrifugal drug analyzer.

We believe our core alcohol detection product line-up continues to be strong. The L-series LX9 and LT7 units have features and performance that have driven market penetration by meeting previously unaddressable market needs, such as smart phone pairing, wider temperature use ranges and fast customization that incorporates local languages. Certified to meet the requirements of most modern registration standards, such as SAI’s (Standards Australia International) latest AS 3547:2019 standards for Breath Alcohol Detectors, our FC-series devices remain popular with many law enforcement and international organizations. Our Easycal® automated calibration station, the only automated calibration available for portable breath alcohol testers, builds valuable protection around our brand and contributes to market share gains by the workplace Phoenix® 6.0 BT and EV 30 devices.

We see our greatest opportunity at the intersection of a growing global demand for rapid drug-of-abuse detection and Lifeloc’s established expertise in creating rugged, intuitive testing equipment. Our current R&D focus is on advancing our SpinDetect™ centrifugal drug-analyzer platform—also known as our “lab-on-a-disk” technology—to deliver a family of portable devices capable of providing rapid, quantitative results for multiple drug classes.

In laboratory testing, the SpinDx system has successfully detected delta-9-THC, cocaine, fentanyl, amphetamine, methamphetamine, morphine, MDMA, and benzodiazepines. These results have been validated against gold-standard liquid chromatography–mass spectrometry (LCMS) testing of human samples, confirming real-world performance at detection limits of approximately 10 ng/ml. Our current development efforts are aimed at improving assay robustness and optimizing disk design so that the entire analysis can be completed within a single disposable cartridge.

We are initiating beta testing of the SpinDetect™ oral-fluid analyzer focused on delta-9-THC detection using a prototype reader, with final component optimization underway under a signed beta-testing agreement. The initial commercial product is expected to measure delta-9-THC—the primary psychoactive compound in cannabis—followed by a multi-drug panel release. We anticipate a commercial launch in 2026, with subsequent expansion into additional drug panels and sample types, including blood and breath. Development of a combined LX9 breathalyzer + THC SpinDx unit will follow as a next-generation roadside marijuana breath testing system. Continued progress toward these milestones will depend on securing additional financing.

“Prototype SpinDetect™ analyzers are now traveling to trade shows for customer demonstrations,” said Dr. Wayne Willkomm, Lifeloc’s President and CEO. “We are encouraged by early engagement and interest as we move closer to market introduction. Rapid oral-fluid drug testing represents our most immediate and scalable growth opportunity, and we believe SpinDetect™ can meet this need effectively. Beyond oral-fluid applications, this platform offers a powerful foundation for testing other sample types and analytes.”

As SpinDetect™ advances toward commercialization, we are also exploring broader applications of our microfluidic technology. The same “lab-on-a-disk” system used to detect drugs of abuse can be adapted to identify other biological or chemical targets—such as food or water contaminants, neonatal or veterinary drug residues, or environmental toxins. This versatility positions Lifeloc to extend the platform into adjacent markets in public health, food safety, and environmental testing. While additional research, licensing, and regulatory clearances will be required, the scalability and analytical precision of the SpinDetect™ platform provide a solid foundation for sustained growth across multiple high-impact sectors.

Lifeloc Technologies shares began trading on the OTCID July 1, 2025 in alignment with the evolving structure of the OTC Markets. OTCID replaced the OTC Pink Current Market for fully reporting companies. The new OTCID standards may create greater market confidence than the OTC Pink and allow a more transparent and liquid marketplace for our shareholders.

About Lifeloc Technologies

Lifeloc Technologies, Inc. (OTC: LCTC) is a trusted U.S. manufacturer of evidential breath alcohol testers and related training and supplies for Workplace, Law Enforcement, Corrections and International customers. Lifeloc stock trades over-the-counter under the symbol LCTC. We are a fully reporting Company with our SEC filings available on our web site, www.lifeloc.com/investor.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which involve substantial risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. All forward-looking statements expressed or implied in this press release, including statements about our strategies, performance, expectations about new and existing products, market demand, economic conditions, acceptance of new and existing products, technologies and opportunities, market size and growth, and return on investments in products and market, are based on information available to us on the date of this document, and we assume no obligation to update such forward-looking statements. Investors are strongly encouraged to review the section titled “Risk Factors” in our SEC filings.

Phoenix® and Easycal® are registered trademarks of Lifeloc Technologies, Inc.

SpinDetect™ is a trademark of Lifeloc Technologies, Inc.

SpinDx™ is a trademark of Sandia Corporation.

Amy Evans 
Lifeloc Technologies, Inc. 
http://www.lifeloc.com 
(303) 431-9500

LIFELOC TECHNOLOGIES, INC.

Condensed Balance Sheets (Unaudited)

LIFELOC TECHNOLOGIES, INC.

Condensed Statements of Income (Loss) (Unaudited)

LIFELOC TECHNOLOGIES, INC.

Condensed Statements of Income (Loss) (Unaudited)

 LIFELOC TECHNOLOGIES, INC.
Condensed Statements of Changes in Stockholders' Equity (Unaudited) 

LIFELOC TECHNOLOGIES, INC.

Condensed Statements of Cash Flows (Unaudited)